When time is of essence and every moment counts, Southern Tier Cancer Care is here…
Welcome to STCC
We realize that you are apprehensive and fearful. By providing professional assistance through education, the latest approved treatments available and most importantly, compassionate care, we are dedicated to guiding patients to hope, help, and healing.
Southern Tier Cancer Care Team is Committed to
Excellence in Providing Comprehensive, Up to date,
Compassionate and Quality care for Cancer Patients.
EMERGENCIES /AFTER HOURS
Please proceed immediately to the nearest emergency room for any medical emergencies especially fever greater than or equal to 100.4 while on chemotherapy.If you need to reach Dr Soni immediately for problems related to cancer or chemotherapy,
Please call the answering service at (716) 559 1105.
Please call your primary physician or emergency room at Olean General Hospital at (716) 375 4149 for any urgent concerns after office hours or if Dr Soni is away.
News & Updates
Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival [Sarcomas]
Despite the rapidly increasing use of [18F]fluorodeoxyglucose (FDG) –positron emission tomography (PET), the comparison of anatomic and functional imaging in the assessment of clinical outcomes has been lacking. In addition, there has not been a rigorous evaluation of how common radiologic criteria or the location of the radiology reader (local v central) compare in the ability to predict benefit. In this study, we aimed to compare the effectiveness of various radiologic response assessments for the prediction of overall survival (OS) within the same data set of patients with sarcoma.Methods
We analyzed assessments made during a clinical trial of a novel IGF1R antibody in Ewing sarcoma: PET Response Criteria in Solid Tumors (PERCIST) for functional imaging and WHO criteria (performed locally and centrally), RECIST, and volumetric analysis for anatomic imaging. We compared the effectiveness of the various criteria for the prediction of progression and survival.Results
For volume analysis, progression—defined as cumulative lesion volume increase of 100% at 6 weeks—was the optimal cutoff for decreased OS (P < .001). Assessment of the day-9 FDG-PET scan was associated with reduced OS in progressors compared with nonprogressors (P = .001) and with improved OS in responders compared with nonresponders. Significant variations in response (18% to 44%) and progression (9% to 50%) were observed between the different criteria. The comparison of central and local interpretation of anatomic imaging produced similar outcomes. PET was superior to anatomic imaging in identification of a response. Volume analysis identified the most responders among the anatomic imaging criteria.Conclusion
An early signal with FDG-PET on day 9 and volume analysis were the best predictors of benefit. Validation of the volumetric analysis is required.
The National Cancer Institute (NCI) announced a collaboration with the Multiple Myeloma Research Foundation (MMRF) to incorporate MMRF's wealth of genomic and clinical data on the disease into the NCI Genomic Data Commons (GDC), a publicly available database.
A fact sheet that describes breast reconstruction after mastectomy, including surgical options, follow-up care, and breast cancer screening after reconstruction.
Cancer Moonshot Task Force and Vice President Detail Necessary Next Steps to Accelerate Cancer Research and Prevention
Advocacy affiliate calls on Congress and state lawmakers to provide necessary funding and take swift action to act to begin implementing recommendations
Public Health Landmark Achieved as 80% by 2018 Colorectal Cancer Screening Campaign Reaches 1,000th Pledge
Nationwide Effort Could Prevent 277,000 Colorectal Cancer Cases and 203,000 Deaths by 2030